PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.

<h4>Background</h4>Pancreatic adenocarcinoma (PDAC) is an incurable cancer without adequate tumor markers. Our previous study has showed a better diagnostic performance of Protein Induced by Vitamin K Absence II (PIVKA-II) compared to currently used PDAC biomarkers. To corroborate our pr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sara Tartaglione, Patrizia Mancini, Valentina Viggiani, Piero Chirletti, Antonio Angeloni, Emanuela Anastasi
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a5f3204e490b4ed8aaa3767eeeae8722
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a5f3204e490b4ed8aaa3767eeeae8722
record_format	dspace
spelling	oai:doaj.org-article:a5f3204e490b4ed8aaa3767eeeae87222021-11-25T06:19:04ZPIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.1932-620310.1371/journal.pone.0251656https://doaj.org/article/a5f3204e490b4ed8aaa3767eeeae87222021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0251656https://doaj.org/toc/1932-6203<h4>Background</h4>Pancreatic adenocarcinoma (PDAC) is an incurable cancer without adequate tumor markers. Our previous study has showed a better diagnostic performance of Protein Induced by Vitamin K Absence II (PIVKA-II) compared to currently used PDAC biomarkers. To corroborate our previous data with a larger sample size and to assess a possible role of PIVKA-II in predicting surgical success. Additionally, to further evaluate the hypothesis of a direct PIVKA-II production by PDAC cells, we examined PIVKA-II tissue expression in a case of PDAC using immunofluorescence.<h4>Methods</h4>We enrolled 76 newly diagnosed PDAC patients and selected 11 patients to determine PIVKA-II levels also after surgical resection. An immunofluorescence (IF) study of PIVKA-II tissue expression was carried out in one of them. PIVKA-II serum values were measured by chemiluminescent enzyme immunoassay method (CLEIA) on LUMIPULSE G1200 (Fujirebio-Europe, Belgium).<h4>Results</h4>PIVKA-II serum levels were above the cut-off at baseline in 71 patients (94%) with a median value of 464 mAU/Ml (range 27-40783 mAU/mL); the sensitivity and specificity were 78.67% and 90.67% respectively. Patients with pre-operative PIVKA-II positivity showed a significant decrease (P < 0.015) of median PIVKA-II serum concentrations after surgery: 820 (91-40783) mAU/mL at diagnosis vs 123 (31-4666) mAU/mL post-operatively. IF assay on PDAC sections demonstrated PIVKA-II expression in cancer cells.<h4>Conclusion</h4>These data are the first showing a decreased PIVKA-II serum levels after surgery in PDAC patients and reporting PIVKA-II expression in PDAC tissue. Further studies are needed to confirm these findings and to determine PIVKA-II usefulness in diagnosing and monitoring PDAC patients.Sara TartaglionePatrizia ManciniValentina ViggianiPiero ChirlettiAntonio AngeloniEmanuela AnastasiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 5, p e0251656 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Sara Tartaglione Patrizia Mancini Valentina Viggiani Piero Chirletti Antonio Angeloni Emanuela Anastasi PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.
description	<h4>Background</h4>Pancreatic adenocarcinoma (PDAC) is an incurable cancer without adequate tumor markers. Our previous study has showed a better diagnostic performance of Protein Induced by Vitamin K Absence II (PIVKA-II) compared to currently used PDAC biomarkers. To corroborate our previous data with a larger sample size and to assess a possible role of PIVKA-II in predicting surgical success. Additionally, to further evaluate the hypothesis of a direct PIVKA-II production by PDAC cells, we examined PIVKA-II tissue expression in a case of PDAC using immunofluorescence.<h4>Methods</h4>We enrolled 76 newly diagnosed PDAC patients and selected 11 patients to determine PIVKA-II levels also after surgical resection. An immunofluorescence (IF) study of PIVKA-II tissue expression was carried out in one of them. PIVKA-II serum values were measured by chemiluminescent enzyme immunoassay method (CLEIA) on LUMIPULSE G1200 (Fujirebio-Europe, Belgium).<h4>Results</h4>PIVKA-II serum levels were above the cut-off at baseline in 71 patients (94%) with a median value of 464 mAU/Ml (range 27-40783 mAU/mL); the sensitivity and specificity were 78.67% and 90.67% respectively. Patients with pre-operative PIVKA-II positivity showed a significant decrease (P < 0.015) of median PIVKA-II serum concentrations after surgery: 820 (91-40783) mAU/mL at diagnosis vs 123 (31-4666) mAU/mL post-operatively. IF assay on PDAC sections demonstrated PIVKA-II expression in cancer cells.<h4>Conclusion</h4>These data are the first showing a decreased PIVKA-II serum levels after surgery in PDAC patients and reporting PIVKA-II expression in PDAC tissue. Further studies are needed to confirm these findings and to determine PIVKA-II usefulness in diagnosing and monitoring PDAC patients.
format	article
author	Sara Tartaglione Patrizia Mancini Valentina Viggiani Piero Chirletti Antonio Angeloni Emanuela Anastasi
author_facet	Sara Tartaglione Patrizia Mancini Valentina Viggiani Piero Chirletti Antonio Angeloni Emanuela Anastasi
author_sort	Sara Tartaglione
title	PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.
title_short	PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.
title_full	PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.
title_fullStr	PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.
title_full_unstemmed	PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.
title_sort	pivka-ii: a biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/a5f3204e490b4ed8aaa3767eeeae8722
work_keys_str_mv	AT saratartaglione pivkaiiabiomarkerfordiagnosingandmonitoringpatientswithpancreaticadenocarcinoma AT patriziamancini pivkaiiabiomarkerfordiagnosingandmonitoringpatientswithpancreaticadenocarcinoma AT valentinaviggiani pivkaiiabiomarkerfordiagnosingandmonitoringpatientswithpancreaticadenocarcinoma AT pierochirletti pivkaiiabiomarkerfordiagnosingandmonitoringpatientswithpancreaticadenocarcinoma AT antonioangeloni pivkaiiabiomarkerfordiagnosingandmonitoringpatientswithpancreaticadenocarcinoma AT emanuelaanastasi pivkaiiabiomarkerfordiagnosingandmonitoringpatientswithpancreaticadenocarcinoma
_version_	1718413943220731904

PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.

Ejemplares similares